PUBLISHER: Grand View Research | PRODUCT CODE: 1790253
PUBLISHER: Grand View Research | PRODUCT CODE: 1790253
Renal Denervation Catheter Market Summary
The global renal denervation catheter market size was estimated at USD 84.91 million in 2025 and is projected to reach USD 453.97 million by 2033, growing at a CAGR of 23.31% from 2025 to 2033. This growth is primarily driven by the increasing global burden of hypertension, particularly treatment-resistant hypertension, which affects a significant proportion of patients who do not respond adequately to pharmacological therapy.
As a minimally invasive procedure, renal denervation (RDN) offers a promising alternative for patients seeking long-term blood pressure control with fewer medications. According to the NIH, hypertension is a critical public health issue and a leading cause of cardiovascular disease, morbidity, and premature mortality worldwide. About 1.13 billion people - one in six globally - are affected by high blood pressure, which is projected to increase to 1.5 billion by 2025.
The rising global prevalence of hypertension is a significant factor fueling the growth of the renal denervation catheter market. Hypertension remains one of the most significant modifiable risk factors for cardiovascular disease, stroke, and kidney failure, and its incidence continues to escalate due to factors such as aging populations, unhealthy lifestyles, obesity, high salt intake, and increasing levels of stress. According to the WHO, as of March 2023, approximately 1.28 billion adults aged 30 to 79 years are affected by hypertension, with two-thirds of them living in low- and middle-income countries. Particularly concerning the subset of this population is those with resistant hypertension-patients who fail to achieve target blood pressure levels despite using three or more antihypertensive medications, including a diuretic. This group represents a key renal denervation therapy target population.
As awareness of the limitations of pharmacologic treatments grows and the demand for more effective, longer-lasting interventions increases, renal denervation is gaining attention as a minimally invasive option to reduce sympathetic nerve activity and achieve sustained blood pressure control. The increasing clinical and real-world evidence supporting RDN's efficacy and safety in lowering blood pressure, especially in resistant hypertension, is driving its acceptance among physicians and patients, significantly contributing to the expansion of the renal denervation catheter market.
Global Renal Denervation Catheter Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2025 to 2033. For this study, Grand View Research has segmented the global renal denervation catheter market report based on product, end use, and region: